Cost Utility of Vaccination Against COVID-19 in Brazil

The objective of this study was to evaluate the cost-utility of the Oxford, CoronaVac, and Janssen COVID-19 vaccines from the perspective of the Brazilian public health system. A total of 3 microsimulation models were constructed with individual data to evaluate the 3 vaccines. The simulation contai...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Value in health regional issues 2022-09, Vol.31, p.18-24
Hauptverfasser: Fernandes, Ricardo Ribeiro Alves, Santos, Marisa da Silva, Magliano, Carlos Alberto da Silva, Tura, Bernardo Rangel, Macedo, Luana Schroeder Damico Nascimento, Padila, Matheus Piccin, França, Ana Cláudia Wekmuller, Braga, Andressa Araujo
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 24
container_issue
container_start_page 18
container_title Value in health regional issues
container_volume 31
creator Fernandes, Ricardo Ribeiro Alves
Santos, Marisa da Silva
Magliano, Carlos Alberto da Silva
Tura, Bernardo Rangel
Macedo, Luana Schroeder Damico Nascimento
Padila, Matheus Piccin
França, Ana Cláudia Wekmuller
Braga, Andressa Araujo
description The objective of this study was to evaluate the cost-utility of the Oxford, CoronaVac, and Janssen COVID-19 vaccines from the perspective of the Brazilian public health system. A total of 3 microsimulation models were constructed with individual data to evaluate the 3 vaccines. The simulation contains 7 transition states that are related to the natural history of the disease. The model with a daily cycle has a time horizon of 1 year and uses data from 289 days of the pandemic. The analysis was conducted from the perspective of the Brazilian public health system considering direct medical costs. For the model inputs, outpatient and hospital databases were used with information on treated patients stratified by age. Information on mortality was also stratified based on patients' age in the mortality database (SIM). The efficacy of vaccines to reduce the likelihood of patients becoming ill was evaluated independently for each vaccine. Information on the quality of life of patients in outpatient or hospital treatment and the sequelae resulting from the disease were extracted from the literature. The main outcome of the analysis was quality-adjusted life-years (QALYs). The vaccines showed incremental cost-utility ratios ranging from R$−23 161.3/QALY (Oxford) to R$17 757.85/QALY (CoronaVac). The older the population, the lower was the incremental cost-utility ratio. Given a willingness-to-pay threshold of R$17 586/QALY, all the vaccines were considered cost-effective in the probabilistic sensitivity analysis. The results of the analysis by age group can help in the preparation of a vaccination prioritization plan. •This is the first economic evaluation performed with COVID-19 vaccines from the perspective of the Brazilian public health system.•The analysis used real-world data on mortality and outpatient and hospital treatment, which represent the context of the first year of the pandemic in Brazil.•The study allowed for a comparison of the cost-utility ratios of 3 different vaccines used in Brazil, taking into account 3 age groups (75 years old), and demonstrating the impact of price and number of doses on the efficiency of health spending.
doi_str_mv 10.1016/j.vhri.2022.01.009
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8935121</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S2212109922000942</els_id><sourcerecordid>2644009619</sourcerecordid><originalsourceid>FETCH-LOGICAL-c455t-d8db1875139a7d1b31bb240fba2dd0cd13dc9df7b9f85e04da17581fbf46a44b3</originalsourceid><addsrcrecordid>eNp9kE1LAzEQhoMoKuof8CB79LJrJsl-BETQ-gmCF-015GtrynajybZQf70ptUUvzmUG5n3fGR6ETgEXgKG6mBaL9-AKggkpMBQY8x10SAiQHACT3c2MOT9AJzFOcaqaYdrgfXRAS0rKitNDVI18HLK3wXVuWGa-zcZSa9fLwfk-u55I16f16GX8dJsDz1yf3QT55bpjtNfKLtqTn36E3u7vXkeP-fPLw9Po-jnXrCyH3DRGQVOXQLmsDSgKShGGWyWJMVgboEZz09aKt01pMTMS6rKBVrWskowpeoSu1rkfczWzRtt-CLITH8HNZFgKL534u-ndu5j4hWg4LYFACjj_CQj-c27jIGYuatt1srd-HgWpGEvsKuBJStZSHXyMwbbbM4DFirmYihVzsWIuMIjkS6az3w9uLRvCSXC5FtiEaeFsEFE722trXLB6EMa7__K_AUdtkio</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2644009619</pqid></control><display><type>article</type><title>Cost Utility of Vaccination Against COVID-19 in Brazil</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Alma/SFX Local Collection</source><creator>Fernandes, Ricardo Ribeiro Alves ; Santos, Marisa da Silva ; Magliano, Carlos Alberto da Silva ; Tura, Bernardo Rangel ; Macedo, Luana Schroeder Damico Nascimento ; Padila, Matheus Piccin ; França, Ana Cláudia Wekmuller ; Braga, Andressa Araujo</creator><creatorcontrib>Fernandes, Ricardo Ribeiro Alves ; Santos, Marisa da Silva ; Magliano, Carlos Alberto da Silva ; Tura, Bernardo Rangel ; Macedo, Luana Schroeder Damico Nascimento ; Padila, Matheus Piccin ; França, Ana Cláudia Wekmuller ; Braga, Andressa Araujo</creatorcontrib><description>The objective of this study was to evaluate the cost-utility of the Oxford, CoronaVac, and Janssen COVID-19 vaccines from the perspective of the Brazilian public health system. A total of 3 microsimulation models were constructed with individual data to evaluate the 3 vaccines. The simulation contains 7 transition states that are related to the natural history of the disease. The model with a daily cycle has a time horizon of 1 year and uses data from 289 days of the pandemic. The analysis was conducted from the perspective of the Brazilian public health system considering direct medical costs. For the model inputs, outpatient and hospital databases were used with information on treated patients stratified by age. Information on mortality was also stratified based on patients' age in the mortality database (SIM). The efficacy of vaccines to reduce the likelihood of patients becoming ill was evaluated independently for each vaccine. Information on the quality of life of patients in outpatient or hospital treatment and the sequelae resulting from the disease were extracted from the literature. The main outcome of the analysis was quality-adjusted life-years (QALYs). The vaccines showed incremental cost-utility ratios ranging from R$−23 161.3/QALY (Oxford) to R$17 757.85/QALY (CoronaVac). The older the population, the lower was the incremental cost-utility ratio. Given a willingness-to-pay threshold of R$17 586/QALY, all the vaccines were considered cost-effective in the probabilistic sensitivity analysis. The results of the analysis by age group can help in the preparation of a vaccination prioritization plan. •This is the first economic evaluation performed with COVID-19 vaccines from the perspective of the Brazilian public health system.•The analysis used real-world data on mortality and outpatient and hospital treatment, which represent the context of the first year of the pandemic in Brazil.•The study allowed for a comparison of the cost-utility ratios of 3 different vaccines used in Brazil, taking into account 3 age groups (&lt;59, 60-75, and &gt;75 years old), and demonstrating the impact of price and number of doses on the efficiency of health spending.</description><identifier>ISSN: 2212-1099</identifier><identifier>ISSN: 2212-1102</identifier><identifier>EISSN: 2212-1102</identifier><identifier>DOI: 10.1016/j.vhri.2022.01.009</identifier><identifier>PMID: 35325693</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Brazil - epidemiology ; Cost-Benefit Analysis ; cost-utility analysis ; COVID-19 ; COVID-19 - prevention &amp; control ; COVID-19 Vaccines - therapeutic use ; health technology assessment ; HTA ; Humans ; Quality of Life ; Themed Section: COVID-19 ; Vaccination ; vaccines</subject><ispartof>Value in health regional issues, 2022-09, Vol.31, p.18-24</ispartof><rights>2022 International Society for Health Economics and Outcomes Research</rights><rights>Copyright © 2022 International Society for Health Economics and Outcomes Research. Published by Elsevier Inc. All rights reserved.</rights><rights>2022 International Society for Health Economics and Outcomes Research. Published by Elsevier Inc. 2022 International Society for Health Economics and Outcomes Research</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c455t-d8db1875139a7d1b31bb240fba2dd0cd13dc9df7b9f85e04da17581fbf46a44b3</citedby><cites>FETCH-LOGICAL-c455t-d8db1875139a7d1b31bb240fba2dd0cd13dc9df7b9f85e04da17581fbf46a44b3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,776,780,881,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35325693$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Fernandes, Ricardo Ribeiro Alves</creatorcontrib><creatorcontrib>Santos, Marisa da Silva</creatorcontrib><creatorcontrib>Magliano, Carlos Alberto da Silva</creatorcontrib><creatorcontrib>Tura, Bernardo Rangel</creatorcontrib><creatorcontrib>Macedo, Luana Schroeder Damico Nascimento</creatorcontrib><creatorcontrib>Padila, Matheus Piccin</creatorcontrib><creatorcontrib>França, Ana Cláudia Wekmuller</creatorcontrib><creatorcontrib>Braga, Andressa Araujo</creatorcontrib><title>Cost Utility of Vaccination Against COVID-19 in Brazil</title><title>Value in health regional issues</title><addtitle>Value Health Reg Issues</addtitle><description>The objective of this study was to evaluate the cost-utility of the Oxford, CoronaVac, and Janssen COVID-19 vaccines from the perspective of the Brazilian public health system. A total of 3 microsimulation models were constructed with individual data to evaluate the 3 vaccines. The simulation contains 7 transition states that are related to the natural history of the disease. The model with a daily cycle has a time horizon of 1 year and uses data from 289 days of the pandemic. The analysis was conducted from the perspective of the Brazilian public health system considering direct medical costs. For the model inputs, outpatient and hospital databases were used with information on treated patients stratified by age. Information on mortality was also stratified based on patients' age in the mortality database (SIM). The efficacy of vaccines to reduce the likelihood of patients becoming ill was evaluated independently for each vaccine. Information on the quality of life of patients in outpatient or hospital treatment and the sequelae resulting from the disease were extracted from the literature. The main outcome of the analysis was quality-adjusted life-years (QALYs). The vaccines showed incremental cost-utility ratios ranging from R$−23 161.3/QALY (Oxford) to R$17 757.85/QALY (CoronaVac). The older the population, the lower was the incremental cost-utility ratio. Given a willingness-to-pay threshold of R$17 586/QALY, all the vaccines were considered cost-effective in the probabilistic sensitivity analysis. The results of the analysis by age group can help in the preparation of a vaccination prioritization plan. •This is the first economic evaluation performed with COVID-19 vaccines from the perspective of the Brazilian public health system.•The analysis used real-world data on mortality and outpatient and hospital treatment, which represent the context of the first year of the pandemic in Brazil.•The study allowed for a comparison of the cost-utility ratios of 3 different vaccines used in Brazil, taking into account 3 age groups (&lt;59, 60-75, and &gt;75 years old), and demonstrating the impact of price and number of doses on the efficiency of health spending.</description><subject>Brazil - epidemiology</subject><subject>Cost-Benefit Analysis</subject><subject>cost-utility analysis</subject><subject>COVID-19</subject><subject>COVID-19 - prevention &amp; control</subject><subject>COVID-19 Vaccines - therapeutic use</subject><subject>health technology assessment</subject><subject>HTA</subject><subject>Humans</subject><subject>Quality of Life</subject><subject>Themed Section: COVID-19</subject><subject>Vaccination</subject><subject>vaccines</subject><issn>2212-1099</issn><issn>2212-1102</issn><issn>2212-1102</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kE1LAzEQhoMoKuof8CB79LJrJsl-BETQ-gmCF-015GtrynajybZQf70ptUUvzmUG5n3fGR6ETgEXgKG6mBaL9-AKggkpMBQY8x10SAiQHACT3c2MOT9AJzFOcaqaYdrgfXRAS0rKitNDVI18HLK3wXVuWGa-zcZSa9fLwfk-u55I16f16GX8dJsDz1yf3QT55bpjtNfKLtqTn36E3u7vXkeP-fPLw9Po-jnXrCyH3DRGQVOXQLmsDSgKShGGWyWJMVgboEZz09aKt01pMTMS6rKBVrWskowpeoSu1rkfczWzRtt-CLITH8HNZFgKL534u-ndu5j4hWg4LYFACjj_CQj-c27jIGYuatt1srd-HgWpGEvsKuBJStZSHXyMwbbbM4DFirmYihVzsWIuMIjkS6az3w9uLRvCSXC5FtiEaeFsEFE722trXLB6EMa7__K_AUdtkio</recordid><startdate>20220901</startdate><enddate>20220901</enddate><creator>Fernandes, Ricardo Ribeiro Alves</creator><creator>Santos, Marisa da Silva</creator><creator>Magliano, Carlos Alberto da Silva</creator><creator>Tura, Bernardo Rangel</creator><creator>Macedo, Luana Schroeder Damico Nascimento</creator><creator>Padila, Matheus Piccin</creator><creator>França, Ana Cláudia Wekmuller</creator><creator>Braga, Andressa Araujo</creator><general>Elsevier Inc</general><general>International Society for Health Economics and Outcomes Research. Published by Elsevier Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20220901</creationdate><title>Cost Utility of Vaccination Against COVID-19 in Brazil</title><author>Fernandes, Ricardo Ribeiro Alves ; Santos, Marisa da Silva ; Magliano, Carlos Alberto da Silva ; Tura, Bernardo Rangel ; Macedo, Luana Schroeder Damico Nascimento ; Padila, Matheus Piccin ; França, Ana Cláudia Wekmuller ; Braga, Andressa Araujo</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c455t-d8db1875139a7d1b31bb240fba2dd0cd13dc9df7b9f85e04da17581fbf46a44b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Brazil - epidemiology</topic><topic>Cost-Benefit Analysis</topic><topic>cost-utility analysis</topic><topic>COVID-19</topic><topic>COVID-19 - prevention &amp; control</topic><topic>COVID-19 Vaccines - therapeutic use</topic><topic>health technology assessment</topic><topic>HTA</topic><topic>Humans</topic><topic>Quality of Life</topic><topic>Themed Section: COVID-19</topic><topic>Vaccination</topic><topic>vaccines</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Fernandes, Ricardo Ribeiro Alves</creatorcontrib><creatorcontrib>Santos, Marisa da Silva</creatorcontrib><creatorcontrib>Magliano, Carlos Alberto da Silva</creatorcontrib><creatorcontrib>Tura, Bernardo Rangel</creatorcontrib><creatorcontrib>Macedo, Luana Schroeder Damico Nascimento</creatorcontrib><creatorcontrib>Padila, Matheus Piccin</creatorcontrib><creatorcontrib>França, Ana Cláudia Wekmuller</creatorcontrib><creatorcontrib>Braga, Andressa Araujo</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Value in health regional issues</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Fernandes, Ricardo Ribeiro Alves</au><au>Santos, Marisa da Silva</au><au>Magliano, Carlos Alberto da Silva</au><au>Tura, Bernardo Rangel</au><au>Macedo, Luana Schroeder Damico Nascimento</au><au>Padila, Matheus Piccin</au><au>França, Ana Cláudia Wekmuller</au><au>Braga, Andressa Araujo</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Cost Utility of Vaccination Against COVID-19 in Brazil</atitle><jtitle>Value in health regional issues</jtitle><addtitle>Value Health Reg Issues</addtitle><date>2022-09-01</date><risdate>2022</risdate><volume>31</volume><spage>18</spage><epage>24</epage><pages>18-24</pages><issn>2212-1099</issn><issn>2212-1102</issn><eissn>2212-1102</eissn><abstract>The objective of this study was to evaluate the cost-utility of the Oxford, CoronaVac, and Janssen COVID-19 vaccines from the perspective of the Brazilian public health system. A total of 3 microsimulation models were constructed with individual data to evaluate the 3 vaccines. The simulation contains 7 transition states that are related to the natural history of the disease. The model with a daily cycle has a time horizon of 1 year and uses data from 289 days of the pandemic. The analysis was conducted from the perspective of the Brazilian public health system considering direct medical costs. For the model inputs, outpatient and hospital databases were used with information on treated patients stratified by age. Information on mortality was also stratified based on patients' age in the mortality database (SIM). The efficacy of vaccines to reduce the likelihood of patients becoming ill was evaluated independently for each vaccine. Information on the quality of life of patients in outpatient or hospital treatment and the sequelae resulting from the disease were extracted from the literature. The main outcome of the analysis was quality-adjusted life-years (QALYs). The vaccines showed incremental cost-utility ratios ranging from R$−23 161.3/QALY (Oxford) to R$17 757.85/QALY (CoronaVac). The older the population, the lower was the incremental cost-utility ratio. Given a willingness-to-pay threshold of R$17 586/QALY, all the vaccines were considered cost-effective in the probabilistic sensitivity analysis. The results of the analysis by age group can help in the preparation of a vaccination prioritization plan. •This is the first economic evaluation performed with COVID-19 vaccines from the perspective of the Brazilian public health system.•The analysis used real-world data on mortality and outpatient and hospital treatment, which represent the context of the first year of the pandemic in Brazil.•The study allowed for a comparison of the cost-utility ratios of 3 different vaccines used in Brazil, taking into account 3 age groups (&lt;59, 60-75, and &gt;75 years old), and demonstrating the impact of price and number of doses on the efficiency of health spending.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>35325693</pmid><doi>10.1016/j.vhri.2022.01.009</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2212-1099
ispartof Value in health regional issues, 2022-09, Vol.31, p.18-24
issn 2212-1099
2212-1102
2212-1102
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8935121
source MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Alma/SFX Local Collection
subjects Brazil - epidemiology
Cost-Benefit Analysis
cost-utility analysis
COVID-19
COVID-19 - prevention & control
COVID-19 Vaccines - therapeutic use
health technology assessment
HTA
Humans
Quality of Life
Themed Section: COVID-19
Vaccination
vaccines
title Cost Utility of Vaccination Against COVID-19 in Brazil
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-19T04%3A46%3A38IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Cost%20Utility%20of%20Vaccination%20Against%20COVID-19%20in%20Brazil&rft.jtitle=Value%20in%20health%20regional%20issues&rft.au=Fernandes,%20Ricardo%20Ribeiro%20Alves&rft.date=2022-09-01&rft.volume=31&rft.spage=18&rft.epage=24&rft.pages=18-24&rft.issn=2212-1099&rft.eissn=2212-1102&rft_id=info:doi/10.1016/j.vhri.2022.01.009&rft_dat=%3Cproquest_pubme%3E2644009619%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2644009619&rft_id=info:pmid/35325693&rft_els_id=S2212109922000942&rfr_iscdi=true